Tissue transglutaminase 2 as a biomarker of @entity3146 ( XXXX ) and its relationship to @entity986 and nuclear factor kappaB expression.

@entity6461 @entity32 @entity2451 @entity986 @entity5 @entity957 @entity281 @entity3799 @entity8265 @entity3146 @entity1141
Tissue transglutaminase 2 ( @entity8265 ) is a recently identified molecule with multifunctional physiological roles. This is the first report of the expression of @entity8265 in @entity3146 ( @entity3146 ) and @entity957 ( @entity6461 ). For comparison, the expression of @entity986 , a known surrogate biomarker of @entity281 , was evaluated. The expression of @entity2451 ( @entity2451 ), a molecule @entity32 and @entity5 , was also determined to explore its possible linkage with @entity8265 expression. Twenty cases each with normal cervical histology, CIN1, CIN2, CIN3, and invasive @entity6461 were analyzed for @entity8265 , @entity986 , and @entity2451 expression by immunohistochemistry. Intergroup differences were analyzed by Friedman ANOVA. Cytoplasmic as well as nuclear @entity8265 expression was observed in the epithelial cells. As compared to normal controls, CIN1 showed markedly increased cytoplasmic @entity8265 expression (p = 0.006). In CIN2/3, additional nuclear @entity8265 expression was seen (p = 0.009 and 0.031, respectively). Marked extracellular stromal upregulation of @entity8265 was noted in CIN3/ @entity6461 versus normal controls (p = 0.054; p = 0.003). There was no relationship of @entity8265 with either @entity986 of @entity2451 expression. Combining @entity8265 immunoreactivity with @entity986 increased the immunolabeling of @entity1141 from 35% to 100% in CIN1, 45% to 60% in CIN2, and 60% to 85% in CIN3. @entity8265 serves as an additional biomarker for all grades of @entity3799 , especially for low-grade @entity1141 .
